The gut microbiota in cancer immunity and immunotherapy

The human gastrointestinal tract harbors trillions of microorganisms, including bacteria, fungi, and viruses, to form the gut microbiota. Cumulative evidence has demonstrated the critical impact of gut microbes on cancer immunity. In cancer, an altered gut microbiota enriched with pathogenic bacteria can actively promote immune evasion and disrupt antitumor immunity, thereby supporting tumor growth and survival. Conversely, beneficial commensal bacteria (e.g., Lactobacillus and Bifidobacterium) have emerged as therapeutic probiotics for cancer prevention and as adjuvants for cancer therapy. The gut microbiota is also closely linked to the efficacy of immunotherapy. This review summarizes the effects of pathogenic bacteria and beneficial commensals, including T cells, B cells, natural killer cells, innate lymphoid cells, and myeloid-derived suppress cells, on various innate and adaptive immune cell populations in cancer. It also explores the mechanisms by which the gut microbiota influences immunotherapy efficacy, such as the modulation of innate immune cells and CD8+ T cells. Given its importance, an increasing number of studies have developed approaches to target the gut microbiota to improve immunotherapy outcomes and reduce immune-related adverse events. These strategies include antimicrobial intervention, probiotics, prebiotics/dietary modifications, microbial metabolites, phage therapy, and fecal microbiota transplantation. This review also evaluates clinical applications that use the gut microbiota to predict immunotherapy outcomes. Overall, the current understanding of host‒microbe interactions within the tumor microenvironment has laid a critical foundation for the translation of microbiota research into clinical practice, ultimately benefiting patients.

• Publication year

  2025

• Venue

  Cellular & Molecular Immunology

• Publication date

  2025-08-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41423-025-01326-2PMID 40770084PMCID 12398524
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CLINICAL DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS.

  2025cited by this paper
• AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity.

  2025cited by this paper
• Microbiome dysbiosis, neutrophil recruitment and mesenchymal transition of mesothelial cells promotes peritoneal metastasis of colorectal cancer

  2025cited by this paper
• Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses.

  2025cited by this paper
• Decoding the Ability of Helicobacter pylori to Evade Immune Recognition and Cause Disease

  2025cited by this paper
• Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON).

  2025cited by this paper
• Intestinal Bacteroides drives glioma progression by regulating CD8+ T cell tumor infiltration.

  2025cited by this paper
• Sex Hormones–Gut Microbiome Axis: An Update of What Is Known So Far

  2025cited by this paper
• Artificial intelligence in bacterial diagnostics and antimicrobial susceptibility testing: Current advances and future prospects.

  2025cited by this paper
• Enhancing immunotherapy with tumour-responsive nanomaterials

  2025cited by this paper
• TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti–PD-1 tumor immunotherapy

  2024cited by this paper
• Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice

  2024cited by this paper
• Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer.

  2024influential reference
• Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis

  2024cited by this paper
• DAMPs and DAMP-sensing receptors in inflammation and diseases.

  2024cited by this paper
• Rapamycin circumvents anti PD-1 therapy resistance in colorectal cancer by reducing PD-L1 expression and optimizing the tumor microenvironment.

  2024cited by this paper
• Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.

  2024cited by this paper
• Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer.

  2024cited by this paper
• Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma

  2024cited by this paper
• CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

  2024cited by this paper
• Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy.

  2024cited by this paper
• Immune evasion by proteolytic shedding of natural killer group 2, member D ligands in Helicobacter pylori infection

  2024cited by this paper
• Oral probiotic extracellular vesicle therapy mitigates Influenza A Virus infection via blunting IL-17 signaling

  2024cited by this paper
• Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-Myc

  2024cited by this paper
• Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer

  2024cited by this paper
• Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec‐15 axis in immune escape

  2024cited by this paper
• Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8+ T cell effector functions.

  2024cited by this paper
• A high-fat diet promotes cancer progression by inducing gut microbiota–mediated leucine production and PMN-MDSC differentiation

  2024cited by this paper
• IgA facilitates the persistence of the mucosal pathogen Helicobacter pylori.

  2024cited by this paper
• Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer.

  2024cited by this paper
• Inosine induces stemness features in CAR-T cells and enhances potency.

  2024cited by this paper
• Fusobacterium nucleatum infection modulates the transcriptome and epigenome of HCT116 colorectal cancer cells in an oxygen-dependent manner

  2024cited by this paper
• Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response.

  2024cited by this paper
• Bifidobacterium breve-derived indole-3-lactic acid ameliorates colitis-associated tumorigenesis by directing the differentiation of immature colonic macrophages

  2024cited by this paper
• The Impact of Artificial Intelligence on Microbial Diagnosis

  2024cited by this paper
• Estrogen-related differences in antitumor immunity and gut microbiome contribute to sexual dimorphism of colorectal cancer

  2024cited by this paper
• Vitamin D regulates microbiome-dependent cancer immunity

  2024cited by this paper
• Dysfunctional circadian clock accelerates cancer metastasis by intestinal microbiota triggering accumulation of myeloid-derived suppressor cells.

  2024cited by this paper
• Urolithin A Hijacks ERK1/2‐ULK1 Cascade to Improve CD8+ T Cell Fitness for Antitumor Immunity

  2024cited by this paper
• Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy.

  2024cited by this paper
• Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment.

  2023cited by this paper
• Engineered skin bacteria induce antitumor T cell responses against melanoma

  2023cited by this paper
• Interaction between gut microbiota and sex hormones and their relation to sexual dimorphism in metabolic diseases

  2023cited by this paper
• Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice

  2023cited by this paper
• Lactobacillus casei combined with Lactobacillus reuteri alleviate pancreatic cancer by inhibiting TLR4 to promote macrophage M1 polarization and regulate gut microbial homeostasis

  2023cited by this paper
• Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis

  2023cited by this paper
• Role of the microbiota in response to and recovery from cancer therapy

  2023cited by this paper
• Faecalibacterium prausnitzii abrogates intestinal toxicity and promotes tumor immunity to increase the efficacy of dual CTLA-4 and PD-1 checkpoint blockade.

  2023cited by this paper
• Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts.

  2023cited by this paper
• Antibacterial Fusobacterium nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐Colonized Bacteria and Enhance Immunotherapy Against Colorectal Cancer

  2023cited by this paper
• C-Type Lectin Receptors-Triggered Antifungal Immunity May Synergize with and Optimize the Effects of Immunotherapy in Hepatocellular Carcinoma

  2023cited by this paper
• Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.

  2023cited by this paper
• Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice.

  2023cited by this paper
• Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

  2023cited by this paper
• Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: Systematic review, improvements and future challenges

  2023cited by this paper
• Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells

  2023cited by this paper
• A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers

  2023cited by this paper
• Probiotic neoantigen delivery vectors for precision cancer immunotherapy

  2023cited by this paper
• Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses

  2023cited by this paper
• Long-chain polyunsaturated lipids associated with responsiveness to anti-PD-1 therapy are colocalized with immune infiltrates in the tumor microenvironment

  2023cited by this paper
• The colibactin-producing Escherichia coli alters the tumor microenvironment to immunosuppressive lipid overload facilitating colorectal cancer progression and chemoresistance

  2023cited by this paper
• A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors

  2023cited by this paper
• Interleukin-10 in cancer immunotherapy: from bench to bedside.

  2023cited by this paper
• Lactobacillus plantarum-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8+ T cell immunity.

  2023cited by this paper
• Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response

  2023cited by this paper
• Hybrid M13 bacteriophage-based vaccine platform for personalized cancer immunotherapy.

  2022cited by this paper
• Intestinal phages interact with bacteria and are involved in human diseases

  2022cited by this paper
• Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy

  2022cited by this paper
• Intestinal microbiota modulates pancreatic carcinogenesis through intratumoral natural killer cells

  2022cited by this paper
• ILC3s select microbiota-specific regulatory T cells to establish tolerance in the gut

  2022cited by this paper
• Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.

  2022cited by this paper
• Donor specific HLA antibody in hematopoietic stem cell transplantation: Implications for donor selection

  2022cited by this paper
• Dysregulation of NK and CD8+T Cells by the Microbiota Promotes the Progression of Lung Cancer

  2022cited by this paper
• Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

  2022cited by this paper
• Effects of microbiota on anticancer drugs: Current knowledge and potential applications

  2022cited by this paper
• CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

  2022cited by this paper
• Mapping the human gut mycobiome in middle-aged and elderly adults: multiomics insights and implications for host metabolic health

  2022influential reference
• Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy.

  2022cited by this paper
• Context-dependent functions of pattern recognition receptors in cancer

  2022cited by this paper
• Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis

  2022cited by this paper
• Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy

  2022cited by this paper
• Bifidobacterium infantis strain YLGB‐1496 possesses excellent antioxidant and skin barrier‐enhancing efficacy in vitro

  2022cited by this paper
• Toll Like Receptor 9 Pathway Mediates Schlafen+-MDSC Polarization During Helicobacter-Induced Gastric Metaplasias

  2022cited by this paper
• Enterotypes of the human gut mycobiome

  2022influential reference
• Dietary Fiber Intake and Gut Microbiota in Human Health

  2022cited by this paper
• The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer.

  2022cited by this paper
• Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

  2022cited by this paper
• A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors.

  2022cited by this paper
• Heterogeneity and origins of myeloid cells

  2022cited by this paper
• Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC

  2022cited by this paper
• The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly.

  2022cited by this paper
• Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

  2022cited by this paper
• The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer

  2022cited by this paper
• A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota

  2022cited by this paper
• Periodontitis pathogen Porphyromonas gingivalis promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils

  2022cited by this paper
• Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions

  2022cited by this paper
• Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer.

  2022cited by this paper
• Inulin prebiotic reinforces host cancer immunosurveillance via ɣδ T cell activation

  2022cited by this paper
• Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

  2022cited by this paper
• Fungal‐induced glycolysis in macrophages promotes colon cancer by enhancing innate lymphoid cell secretion of IL‐22

  2021cited by this paper

• Harnessing the microbiome for cancer therapy.

  2026cites this paper
• Self-assemblies from prodrugs composed of antimicrobial peptides: a revolution in local lung cancer treatment, with microbiota as a main actor.

  2026cites this paper
• Gut microbiota drives cancer evolution and therapy resistance

  2026cites this paper
• Next-generation cancer therapies: translating experimental advances into clinical practice.

  2026cites this paper
• Gut microbiome–driven colorectal cancer via immune, metabolic, neural, and endocrine axes reprogramming

  2026influential citation
• Reprogramming Gastric Cancer Therapy: A Microbiome-Guided Approach to Precision Oncology

  2026cites this paper
• Metabolic Checkpoints in CD8+ T Cells within the Tumor Microenvironment: A Comprehensive Review and Emerging Insights

  2026cites this paper
• The Role of the Oral Microbiome in Modulating Therapeutic Outcomes in Lung Cancer: Key Commensals and Clinical Implications.

  2026cites this paper
• Unraveling the potential of targeting methionine metabolism in cancer.

  2026cites this paper
• Immune checkpoint inhibitor therapy for gastric cancer: current status, therapeutic challenges, and future prospects

  2026cites this paper
• Harnessing the Gut Microbiota to Improve Cancer Immunotherapy: Focus on Lung Cancer.

  2026cites this paper
• Gastrointestinal dysfunction after brain injury: Mechanisms and the role of the brain-gut axis

  2026cites this paper
• Critical role of reproductive tract microbiota and derived metabolites in inflammation, tumor immunity, and tumorigenesis of gynecological cancers: a narrative review

  2026cites this paper
• Elucidating cellular origins and TME dynamic evolution in NSCLC through multi-omics technologies.

  2025cites this paper
• Role of Gut Microbiome in Oncogenesis and Oncotherapies

  2025cites this paper
• The human microbiome in clinical translation: from bench to bedside

  2025cites this paper
• The microbiome as a therapeutic co-driver in melanoma immuno-oncology

  2025cites this paper
• Omega-3 polyunsaturated fatty acids and gut microbiota

  2025cites this paper
• Applications of traditional Chinese medicine in cancer immunotherapy via gut microbiota modulation: Current status, mechanisms, challenges and perspectives.

  2025cites this paper
• Anna Karenina Principle, Immune‐Oncology‐Microbiome Trio and Cancer Microbiome Therapy

  2025cites this paper
• From Dysbiosis to Diagnosis: The Role of Gut Microbiota in Breast Cancer Etiology and Management

  2025cites this paper
• Gut microbiota–derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy

  2025cites this paper
• Unveiling the interplay between microbiota and PD1/PD-L1 axis in tumor immunity and immunotherapy

  2025cites this paper
• Association Between Oxidative Balance Score and Gynecological Cancer Using NHANES 2011–2018 Data

  2025cites this paper
• The gut microbiome as a potential predictive biomarker for breast cancer: emerging association and geographic differences

  2025cites this paper
• Gut microbial diversity and compositional shifts are associated with differential tumor growth rates in mice

  2025cites this paper
• Gut microbiota reshaping the pancreatic cancer immune microenvironment: new avenues for immunotherapy

  2025cites this paper